Korro to Participate in Upcoming September Investor and Scientific ConferencesGlobeNewsWire • 08/27/24
Korro Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/13/24
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International ConferenceGlobeNewsWire • 05/20/24
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerGlobeNewsWire • 05/14/24
Korro Reports Full Year 2023 Financial Results and Highlights Recent ProgressGlobeNewsWire • 03/26/24
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032Seeking Alpha • 03/14/24
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to TradeZacks Investment Research • 02/27/24
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?Zacks Investment Research • 02/09/24
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing PortfolioGlobeNewsWire • 01/18/24
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 12/07/23
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?The Motley Fool • 12/02/23